IGH gene rearrangements are considered to be one of the classical cytogenetic gene aberrations associated with numerous cancers such as: Chronic lymphocytic leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin lymphoma1, 2, 3. Chromosomal rearrangements involving the IGH gene have been identified in 70% of MM patients, 50% of non-Hodgkin’s lymphoma patients, and 16% of CLL patients2, 4, 5.
Cytogenetic abnormalities involving the IGH gene give rise to unique gene rearrangement patterns that are used to characterize the molecular pathogenesis of multiple myeloma6. IGH gene rearrangement partners such as FGFR3 have been identified as recurrent chromosomal rearrangements and are used to stratify patients with different diseases phenotypes 7, 8.